UK markets closed
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • FTSE 250

    22,537.89
    -742.07 (-3.19%)
     
  • AIM

    1,181.62
    -22.34 (-1.86%)
     
  • GBP/EUR

    1.1779
    -0.0100 (-0.84%)
     
  • GBP/USD

    1.3342
    +0.0022 (+0.16%)
     
  • BTC-GBP

    40,741.77
    -670.15 (-1.62%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • DOW

    34,899.34
    -905.04 (-2.53%)
     
  • CRUDE OIL

    68.15
    -10.24 (-13.06%)
     
  • GOLD FUTURES

    1,788.10
    +1.20 (+0.07%)
     
  • NIKKEI 225

    28,751.62
    -747.66 (-2.53%)
     
  • HANG SENG

    24,080.52
    -659.64 (-2.67%)
     
  • DAX

    15,257.04
    -660.94 (-4.15%)
     
  • CAC 40

    6,739.73
    -336.14 (-4.75%)
     

Borregaard ASA: EBITDA1 NOK 391 million in the 3rd quarter

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Borregaard’s operating revenues reached NOK 1,429 million (NOK 1,260 million)2 in the 3rd quarter of 2021. EBITDA increased to NOK 391 million (NOK 266 million). BioSolutions’ result improved significantly. Fine Chemicals also improved, whereas BioMaterials had a result in line with last year. The net currency impact on EBITDA was slightly positive compared with the 3rd quarter of 2020.

The continued impact from increased sales prices and a favourable product mix were the main reasons for the EBITDA improvement in BioSolutions. For BioMaterials, high deliveries and reduced wood costs compensated for reduced sales prices and increased energy costs. High sales volume and increased sales price for bioethanol contributed to the improvement in Fine Chemicals. High spot prices for liquefied natural gas and electricity led to increased energy costs in all business areas.

Profit before tax was NOK 269 million (NOK 133 million). Earnings per share was NOK 2.12 (NOK 1.12).

- We are pleased both with the result improvement and the strong performance in BioSolutions. Generally, the markets were strong for all business segments, says President and CEO Per A. Sørlie.

Contacts:
Director Investor Relations, Jørn Syvertsen, +47 958 36 335
Director Communication, Tone Horvei Bredal, +47 924 67 711

1. Operating profit before depreciation, amortisation and other income and expenses
2. Figures in parentheses are for the corresponding period in the preceding year

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.


Attachments


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting